Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07685717 · ClinicalTrials.gov registry record · Phase 2
Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
A Phase 2 study, sponsored by Jennifer Woyach.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT07685717 is a Phase 2 study that is actively recruiting participants, run by Jennifer Woyach. The registered enrollment target is 50 participants.
The verdict
NCT07685717, a Phase 2 study, is actively recruiting participants, sponsored by Jennifer Woyach.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This phase II trial studies how well pirtobrutinib works in treating elderly patients with chronic lymphocytic leukemia (CLL). Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib work by blocking the action of the BTK protein that signals cancer cells to multiply. These are very effective, tolerable, and commonly used to treat people with CLL, but they may lead to drug resistance over time. Pirtobrutinib, also a BTK inhibitor, may work better in treating elderly patients with CLL.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Bone Marrow Aspiration
- PROCEDURE Bone Marrow Biopsy
- PROCEDURE Computed Tomography
- OTHER Electronic Health Record Review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07685717
The ClinicalTrials.gov registry entry for NCT07685717 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jennifer Woyach, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07685717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07685717 about?
NCT07685717 is a clinical study titled "Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia". This phase II trial studies how well pirtobrutinib works in treating elderly patients with chronic lymphocytic leukemia (CLL). Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib work by blocking the action of the BTK protein that signals cancer cells to multip...
What is the current status of trial NCT07685717?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2026-08-01. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT07685717?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Aspiration (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Computed Tomography (PROCEDURE), Electronic Health Record Review (OTHER).
Who is sponsoring clinical trial NCT07685717?
This trial is sponsored by Jennifer Woyach, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.